1 Kim, J. H. et al. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders. Movement disorders : official journal of the Movement Disorder Society 17, 1354-1359, doi:10.1002/mds.10255 (2002).
2 Srivanitchapoom, P., Pandey, S. & Hallett, M. Drooling in Parkinson's disease: a review. Parkinsonism Relat Disord 20, 1109-1118, doi:10.1016/j.parkreldis.2014.08.013 (2014).
3 Davydov, L. & Botts, S. R. Clozapine-Induced Hypersalivation. Annals of Pharmacotherapy 34, 662-665, doi:10.1345/aph.19259 (2000).
4 Sockalingam, S., Shammi, C. & Remington, G. Clozapine-Induced Hypersalivation: A Review of Treatment Strategies. The Canadian Journal of Psychiatry 52, 377-384, doi:10.1177/070674370705200607 (2007).
5 Chengappa, K. N. et al. Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol 20, 311-316, doi:10.1097/00004714-200006000-00004 (2000).
6 Corrigan, F. M., MacDonald, S. & Reynolds, G. P. Clozapine-induced hypersalivation and the alpha2 adrenoceptor. British Journal of Psychiatry 167, 412-412, doi:10.1192/bjp.167.3.412a (1995).
7 Zorn, S. H., Jones, S. B., Ward, K. M. & Liston, D. R. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol 269, R1-2, doi:10.1016/0922-4106(94)90047-7 (1994).
8 Parr-Brownlie, L. C. & Hyland, B. I. Bradykinesia Induced by Dopamine D2 Receptor Blockade Is Associated with Reduced Motor Cortex Activity in the Rat. The Journal of Neuroscience 25, 5700-5709, doi:10.1523/jneurosci.0523-05.2005 (2005).
9 Salem, H., Nagpal, C., Pigott, T. & Teixeira, A. L. Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges. Curr Neuropharmacol 15, 789-798, doi:10.2174/1570159X14666161208153644 (2017).
10 Gelb, D. J., Oliver, E. & Gilman, S. Diagnostic Criteria for Parkinson Disease. Archives of Neurology 56, 33-39, doi:10.1001/archneur.56.1.33 (1999).
11 Baik, J. H. et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377, 424-428, doi:10.1038/377424a0 (1995).
12 Bermanzohn, P. C. & Siris, S. G. Akinesia: A syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Comprehensive Psychiatry 33, 221-232, doi:https://doi.org/10.1016/0010-440X(92)90045-R (1992).
13 Winograd-Gurvich, C., Fitzgerald, P. B., Georgiou-Karistianis, N., Bradshaw, J. L. & White, O. B. Negative symptoms: A review of schizophrenia, melancholic depression and Parkinson's disease. Brain Research Bulletin 70, 312-321, doi:https://doi.org/10.1016/j.brainresbull.2006.06.007 (2006).
14 Inada, T. DIEPSS: A second-generation rating scale for antipsychotic-induced extrapyramidal symptoms: Drug-induced Extrapyramidal Symptoms Scale. (Seiwa Shoten, 2009).
15 Kaiser, H. F. A second generation little jiffy. Psychometrika 35, 401-415, doi:10.1007/BF02291817 (1970).
16 BARTLETT, M. S. THE EFFECT OF STANDARDIZATION ON A χ2 APPROXIMATION IN FACTOR ANALYSIS. Biometrika 38, 337-344, doi:10.1093/biomet/38.3-4.337 (1951).
17 Kaiser, H. F. An index of factorial simplicity. Psychometrika 39, 31-36, doi:10.1007/BF02291575 (1974).
18 Child, D. The Essentials of Factor Analysis. (2006).
19 Bentler, P. M. Comparative fit indexes in structural models. Psychological bulletin 107, 238-246 (1990).
20 Browne, M. W. & Cudeck, R. Alternative Ways of Assessing Model Fit. Sociological Methods & Research 21, 230-258, doi:10.1177/0049124192021002005 (1992).
21 MacCallum, R. C. & Hong, S. Power Analysis in Covariance Structure Modeling Using GFI and AGFI. Multivariate Behavioral Research 32, 193-210, doi:10.1207/s15327906mbr3202_5 (1997).
22 Akaike, H. Factor analysis and AIC. Psychometrika 52, 317-332, doi:10.1007/bf02294359 (1987).